UBS Initiates Coverage On Janux Therapeutics with Buy Rating, Announces Price Target of $69
Portfolio Pulse from Benzinga Newsdesk
UBS analyst David Dai has initiated coverage on Janux Therapeutics with a Buy rating and set a price target of $69.
October 24, 2024 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS has initiated coverage on Janux Therapeutics with a Buy rating and a price target of $69, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target by a major financial institution like UBS is likely to positively influence investor sentiment and could lead to an increase in the stock price of Janux Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100